[{"address1": "80 Guest Street", "address2": "Suite 601", "city": "Boston", "state": "MA", "zip": "02135", "country": "United States", "phone": "617 500 8099", "website": "https://www.compasstherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Dr. Thomas J. Schuetz M.D., Ph.D.", "age": 63, "title": "CEO & Vice Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 994800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Shin J.D., M.B.A.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 406256, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan E. Anderman J.D.", "title": "Senior VP, General Counsel & Corporate Secretary", "fiscalYear": 2024, "totalPay": 541620, "exercisedValue": 0, "unexercisedValue": 6250}, {"maxAge": 1, "name": "Mr. Neil L. Lerner CPA", "age": 57, "title": "Senior VP & Chief Accounting Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Anna  Gifford", "title": "Communications Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karin  Herrera B.A.", "title": "Senior VP & Head of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James  Kranz Ph.D.", "title": "VP and Head of Chemistry Manufacturing & Controls", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.85, "open": 4.85, "dayLow": 4.81, "dayHigh": 5.0, "regularMarketPreviousClose": 4.85, "regularMarketOpen": 4.85, "regularMarketDayLow": 4.81, "regularMarketDayHigh": 5.0, "payoutRatio": 0.0, "beta": 1.299, "forwardPE": -9.54902, "volume": 2505145, "regularMarketVolume": 2505145, "averageVolume": 1650033, "averageVolume10days": 2134280, "averageDailyVolume10Day": 2134280, "bid": 4.84, "ask": 4.89, "bidSize": 4, "askSize": 4, "marketCap": 866188416, "fiftyTwoWeekLow": 1.33, "fiftyTwoWeekHigh": 5.11, "allTimeHigh": 11.0, "allTimeLow": 0.765, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 4.0146, "twoHundredDayAverage": 2.934425, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 656160448, "profitMargins": 0.0, "floatShares": 107997868, "sharesOutstanding": 177862102, "sharesShort": 16699205, "sharesShortPriorMonth": 14815308, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0939, "heldPercentInsiders": 0.10986, "heldPercentInstitutions": 0.82945, "shortRatio": 9.04, "shortPercentOfFloat": 0.14840001, "impliedSharesOutstanding": 177862102, "bookValue": 1.18, "priceToBook": 4.1271186, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -65806000, "trailingEps": -0.45, "forwardEps": -0.51, "enterpriseToEbitda": -9.239, "52WeekChange": 2.2333333, "SandP52WeekChange": 0.09209216, "quoteType": "EQUITY", "currentPrice": 4.87, "targetHighPrice": 30.0, "targetLowPrice": 7.0, "targetMeanPrice": 12.72727, "targetMedianPrice": 10.0, "recommendationMean": 1.18182, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 219895008, "totalCashPerShare": 1.236, "ebitda": -71024000, "totalDebt": 9867000, "quickRatio": 17.716, "currentRatio": 17.815, "totalRevenue": 0, "debtToEquity": 4.707, "revenuePerShare": 0.0, "returnOnAssets": -0.23469, "returnOnEquity": -0.37818, "grossProfits": 0, "freeCashflow": -22006376, "operatingCashflow": -45051000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "CMPX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Compass Therapeutics, Inc.", "longName": "Compass Therapeutics, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 0.412371, "regularMarketPrice": 4.87, "corporateActions": [], "postMarketTime": 1763771250, "regularMarketTime": 1763758800, "exchange": "NCM", "messageBoardId": "finmb_266166780", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "epsTrailingTwelveMonths": -0.45, "epsForward": -0.51, "epsCurrentYear": -0.4325, "priceEpsCurrentYear": -11.260116, "fiftyDayAverageChange": 0.8554001, "fiftyDayAverageChangePercent": 0.21307231, "twoHundredDayAverageChange": 1.9355748, "twoHundredDayAverageChangePercent": 0.65960956, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-11-02", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1617629400000, "postMarketChangePercent": 0.37988353, "postMarketPrice": 4.8885, "postMarketChange": 0.018500328, "regularMarketChange": 0.02, "regularMarketDayRange": "4.81 - 5.0", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1650033, "fiftyTwoWeekLowChange": 3.54, "fiftyTwoWeekLowChangePercent": 2.661654, "fiftyTwoWeekRange": "1.33 - 5.11", "fiftyTwoWeekHighChange": -0.24000025, "fiftyTwoWeekHighChangePercent": -0.04696678, "fiftyTwoWeekChangePercent": 223.33333, "earningsTimestampStart": 1762867800, "earningsTimestampEnd": 1762867800, "earningsCallTimestampStart": 1754913600, "earningsCallTimestampEnd": 1754913600, "isEarningsDateEstimate": true, "displayName": "Compass Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-22"}]